Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070161 · ClinicalTrials.gov registry record · Phase 2
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00070161 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 68 participants.
The verdict
NCT00070161, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
RATIONALE: Donepezil and EGb761 may be effective in improving neurocognitive function (such as thinking, attention, concentration, and memory) and may improve quality of life in patients who have undergone radiation therapy to the brain. PURPOSE: This phase II trial is studying how well donepezil or EGb761 works in improving neurocognitive function in patients who have undergone radiation therapy for primary brain tumor or brain metastases.
Interventions
- PROCEDURE cognitive assessment
- DRUG donepezil hydrochloride
- DIETARY_SUPPLEMENT EGb761
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2001-07-01 |
| Est. Completion | 2012-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070161
The ClinicalTrials.gov registry entry for NCT00070161 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cognitive assessment is the first listed.
NCT00070161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00070161 about?
NCT00070161 is a clinical study titled "Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor". RATIONALE: Donepezil and EGb761 may be effective in improving neurocognitive function (such as thinking, attention, concentration, and memory) and may improve quality of life in patients who have undergone radiation therapy to the brain. PURPOSE: This phase II trial is studying how well donepezil o...
What is the current status of trial NCT00070161?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2001-07-01. Estimated completion is 2012-08-01.
What interventions are being tested in trial NCT00070161?
The interventions under investigation include: cognitive assessment (PROCEDURE), donepezil hydrochloride (DRUG), EGb761 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00070161?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.